Background: The entire population of Mozambique is at risk for malaria, which remains one of the leading causes of death. The 2017-2022 National Malaria Strategic Plan focuses on reducing malaria morbidity and mortality in high- and low-transmission areas. This study aimed to estimate the costs and healt...
Background: Due to the threat of emerging anti-malarial resistance, the World Health Organization recommends incorporating surveillance for molecular markers of anti-malarial resistance into routine therapeutic efficacy studies (TESs). In 2018, a TES of artemether-lumefantrine (AL) and artesunate-amodiaq...
Antimalarials/pharmacology,
Antimalarials/therapeutic use,
Artemisinins/pharmacology,
Artemisinins/therapeutic use,
Drug Resistance/genetics,
Drug Therapy, Combination,
Genetic Markers,
Plasmodium falciparum/radiation effects,
Plasmodium falciparum/genetics,
Plasmodium falciparum/isolation & purification,
Polymorphism, Genetic/genetics,
Mozambique
Gupta, himanshu;
Bassat, quique;
Nhamussua, lidia;
Matambisso, gloria;
Cisteró, pau;
Huijben, silvie;
Chidimatembue, arlindo;
Galatas, beatriz;
Ménard, didier;
Ringwald, pascal;
Rabinovich, regina;
Alonso, pedro L;
Saute, francisco;
Assessor, pedro;
Prefeito, alfredo.
Background Mass drug administration (MDA) can rapidly reduce the burden of Plasmodium falciparum (Pf). However, concerns remain about its contribution to select for antimalarial drug resistance. Methods We used Sanger sequencing and real-time PCR to determine the proportion of molecular markers associate...
Antimalarials/administration & dosage,
Antimalarials/pharmacology,
Antimalarials/therapeutic use,
Artemisinins/administration & dosage,
Artemisinins/pharmacology,
Artemisinins/therapeutic use,
Antineoplastic Combined Chemotherapy Protocols,
Drug Resistance/genetics,
Malaria/parasitology,
Malaria/prevention & control,
Mozambique,
Plasmodium falciparum/immunology,
Plasmodium falciparum/genetics,
Plasmodium falciparum/pathogenicity,
Polymorphism, Genetic,
Protozoan Proteins/genetics,
Protozoan Proteins/metabolism,
Quinolines/administration & dosage,
Quinolines/therapeutic use,
Quinolines/pharmacology
Salvador, Crizolgo;
Rafael, Bernardete;
Matsinhe, Francisco;
Matsinhe, Francisco;
Candrinho , Baltazar;
Muthemba , Rosália;
Carvalho, Eva;
Naueia, Eva;
Sacarlal, Jahit;
Namboze, Josephine;
Tiago , Armindo;
Warsame, Marian;
Enosse, Sónia.
he resistance of Plasmodium falciparum to anti-malarial drugs continues to challenge malaria control. We assessed the therapeutic efficacy and safety of artemether-lumefantrine (AL), the first-line treatment of uncomplicated P. falciparum malaria, in children under five years of age in Mozambique. We con...
Antimalarials/therapeutic use,
Artemisinins/therapeutic use,
Malaria/epidemiology,
d0109630,
d0200660,
d0161330,
Artemether, Lumefantrine Drug Combination,
Drug Combinations,
Ethanolamines/therapeutic use,
Fluorenes/therapeutic use,
Malaria, Falciparum/therapy,
Malaria, Falciparum/epidemiology,
Malaria, Falciparum/parasitology,
Plasmodium falciparum/genetics,
Polymerase Chain Reaction,
Mozambique/epidemiology
Kovacs, stephanie d;
Eijk, anna maria van;
Sevene, esperanca;
Dellicour, stephanie;
Weiss, noel, s;
Emerson, scott;
Steketee, richard;
Kuile, feiko O. ter;
Stergachis, andy.
Given the high morbidity for mother and fetus associated with malaria in pregnancy, safe and efficacious drugs are needed for treatment. Artemisinin derivatives are the most effective antimalarials, but are associated with teratogenic and embryotoxic effects in animal models when used in early pregnancy....
Abortion, Spontaneous,
Antimalarials/adverse effects,
Antimalarials/therapeutic use,
Artemisinins/adverse effects,
Artemisinins/therapeutic use,
Cohort Studies,
Malaria/drug therapy,
Pregnancy Complications, Parasitic/drug therapy,
Malaria
Adjei, aexander;
Bana, solomon narh;
Amu, alberta;
Kukula, vida;
Nagai, richard afedi;
Agyei, seth owusu;
Oduro, abraham;
Macete, Eusebio;
Abdulla, salim;
Halidou, tinto;
Sie, ali;
Osei, isaac;
Sevene, esperance;
Asante, kwaku-poku;
Mulokozi, abdunoor;
Compaore, guillaume;
Valea, innocent;
Adjuik, martin;
Baiden, rita;
Ogutu, Bernhards;
Binka, fred;
Gyapong, margaret.
Background: Dihydroartemisinin-piperaquine (DHA-PQ) is one of five WHO recommended artemisinin combination therapy (ACT) for the treatment of uncomplicated malaria. However, little was known on its post-registration safety and effectiveness in sub-Saharan Africa. DHA-PQ provides a long post-treatment pro...
Tint, Halidou;
Seveno, Esperança;
Dellicour, Stephanie;
Calip, Gregory S;
D'Alessandro, Umberto;
Macete, Eusébio;
Diallo , Seydou Nakanabo;
Kazienga, Adama;
Valea, Innocent;
Sorgho, Hermann;
Valá, Anifa;
Augusto, Orvalho;
Ruperez, Clara;
Menendez, Clara;
Ouma, Peter;
Desai, Meghna;
Kuile, Feiko Ter;
Stergachis, Andy.
Background: A major unresolved safety concern for malaria case management is the use of artemisinin combination therapies (ACTs) in the first trimester of pregnancy. There is a need for human data to inform policy makers and treatment guidelines on the safety of artemisinin combination therapies (ACT) wh...
Antimalarials/adverse effects,
Artemisinins/adverse effects,
Clinical Protocols,
Cohort Studies,
Drug Administration Schedule,
Gestational Age,
Malaria/therapy,
Maternal-Fetal Exchange,
Patient Selection,
Pharmacovigilance,
Pregnancy Complications, Parasitic/therapy,
Pregnancy Outcome,
Pregnancy Trimester, First,
Prenatal Exposure Delayed Effects,
Prospective Studies,
Research Design,
Sample Size,
Mozambique,
Burkina Faso,
Kenya,
Antimalarials/therapeutic use,
Artemisinins/therapeutic use
Nhama, Abel;
Bassat 1, Quique;
Enosse, Sónia;
Nhacolo, Arsenio;
Mutemba, Rosália;
Carvalho, Eva;
Naueia, Eva;
Sevene, Esperança;
Guinovart, Caterina;
Warsame, Marian;
Sanz, Sergi;
Mussa, Abdul;
Matsinhe, Graça;
Alonso, Pedro;
Tiago, Armindo;
Macete, Eusebio.
Background: Mozambique adopted artemisinin-based combination therapy (ACT) for the treatment of uncomplicated Plasmodium falciparum malaria in the year 2006, and since 2009 artemether-lumefantrine (AL) and artesunateamodiaquine (ASAQ) have been proposed as alternative first-line treatments. A multicentre...
Amodiaquine/therapeutic use,
Antimalarials/adverse effects,
Antimalarials/therapeutic use,
Artemether, Lumefantrine Drug Combination,
Artemisinins/adverse effects,
Artemisinins/therapeutic use,
Drug Combinations,
Ethanolamines/adverse effects,
Ethanolamines/therapeutic use,
Artesunate/therapeutic use,
Fluorenes/therapeutic use,
Malaria, Falciparum/drug therapy,
Malaria, Falciparum/epidemiology,
Artemether, Lumefantrine Drug Combination/therapeutic use,
Mozambique/epidemiology
Nhama, Abel;
Bassat, Quique;
Enosse, Sónia;
Nhacolo, Arsenio;
Mutemba, Rosália;
Carvalho, Eva;
Naueia, Eva;
Sevene, Esperança;
Guinovart, Caterina;
Warsame, Marian;
Sanz, Sergi;
Mussa, Abdul;
Matsinhe, Graça;
Alonso, Pedro;
Tiago, Armindo;
Macete, Eusebio.
Background: Mozambique adopted artemisinin-based combination therapy (ACT) for the treatment of uncomplicated Plasmodium falciparum malaria in the year 2006, and since 2009 artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) have been proposed as alternative first-line treatments. A multicentr...
Amodiaquine/adverse effects,
Amodiaquine/therapeutic use,
Antimalarials/adverse effects,
Antimalarials/therapeutic use,
Artemether, Lumefantrine Drug Combination,
Artemisinins/adverse effects,
Artemisinins/therapeutic use,
Drug Combinations,
Ethanolamines/adverse effects,
Ethanolamines/therapeutic use,
Fluorenes/adverse effects,
Fluorenes/therapeutic use,
Kaplan-Meier Estimate,
Malaria, Falciparum/drug therapy,
Malaria, Falciparum/epidemiology,
Treatment Outcome,
Mozambique/epidemiology
